Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 16/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900032 | 0.90 | PIK3CA (0.66) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL477673 | 0.89 | PIK3CB (0.77) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL477736 | 0.86 | PIK3CB (0.80) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL952221 | 0.85 | PIK3CB (0.83) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL477550 | 0.85 | PIK3CA (0.68) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL3563102 | 0.84 | PIK3CB (1.00) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL899498 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL909478 | 0.83 | PIK3CA (0.81) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL909456 | 0.83 | PIK3CA (0.76) | PIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL477551 | 0.83 | PIK3CA (0.64) | PIK3CAPIK3CBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |